Articles

GENUINE, the first randomized phase 3 trial conducted to assess the addition of a novel agent, ublituximab, to ibrutinib in high-risk, relapsed/refractory chronic lymphocytic leukemia (CLL), evaluates ibrutinib monotherapy versus ublituximab and ibrutinib. Read More ›

This retrospective cohort study examines the use and efficacy of ibrutinib in patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and Richter transformation. Read More ›

MMY1001 is an open-label phase 1b study of daratumumab in combination with carfilzomib, lenalidomide, and dexamethasone in newly diagnosed patients with multiple myeloma. Read More ›

The combination of elotuzumab, bortezomib, lenalidomide, and dexamethasone is effective in patients with newly diagnosed multiple myeloma (MM). Read More ›

A phase 1b study showed that isatuximab is clinically active in patients with relapsed/refractory multiple myeloma. Read More ›

The combination of bendamustine and pomalidomide with dexamethasone shows promise in patients with relapsed/refractory multiple myeloma (RRMM). Read More ›

The DSMM XIV study highlights the efficacy of bortezomib versus doxorubicin in combination with lenalidomide and dexamethasone prior to stem-cell transplant in patients with newly diagnosed multiple myeloma. Read More ›

The Myeloma XI Study analyzed lenalidomide induction and maintenance therapy in transplant-eligible patients with myeloma. Read More ›

Researchers are evaluating ibrutinib with prednisone as a potential treatment option for patients with newly diagnosed moderate or severe chronic graft-versus-host disease (cGVHD). Read More ›

Results from the KEYNOTE-023 trial show that the combination of pembrolizumab plus lenalidomide and low-dose dexamethasone is efficacious in patients with relapsed/refractory multiple myeloma (RRMM). Read More ›